Taltz was approved by the Food and Drug Administration (FDA) in March 2016 for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy. Eli Lilly is also launching the Taltz Together program that will offer patients injection training, guidance on insurance benefits, and assistance in filling Taltz prescription within the contracted network of specialty pharmacies. The Companion in Care program will also offer a patient representative to answer questions and concerns.
Taltz is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.
Taltz injection is available as an 80mg/mL strength single-dose autoinjector in 1-, 2-, and 3-count cartons as well as a single-dose prefilled syringe in 1-, 2-, and 3-count cartons.
For more information call (800) 545-5979 or visit Taltz.com.